wrans/answers2025-02-11 conversation_145
Source: hansard.parliament.uk (2025-02-11)

UK Parliament Hansard data: wrans/answers2025-02-11 conversation_145

Peter Fortune:To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into alcoholic fatty liver disease in the 2023-24 financial year; and which public bodies provided that funding. \p Feryal Clark: The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.

UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.

Details of UKRI and NIHR funding on specific areas is provided in the table below:

UIN

NIHR funding in FY 2023/24

UKRI Funding in FY 2023/24

28175

Hepatitis B

NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.

The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.

28176

Hepatitis C

UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.

28177

Hepatocellular carcinoma

NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.

The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).

28178

Cholangiocarcinoma

NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24

The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.

28179

Biliary cirrhosis

NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24

UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.

28180

Sclerosing cholangitis

NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24

UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.

28181

Autoimmune hepatitis

NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24

UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.

28182

Non-alcoholic fatty liver disease

NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.

The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).

28183

Alcoholic fatty liver disease

UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.